Omid Iravani1, George Wai-Cheong Yip1, Aye Aye Thike2, Pei Jou Chua1, Olivia Jane Scully1, Puay-Hoon Tan3, Boon-Huat Bay1. 1. Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 2. Department of Pathology, Singapore General Hospital, Singapore, Singapore. 3. Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore Department of Pathology, Singapore General Hospital, Singapore, Singapore.
Abstract
AIMS: Altered expression of the Claudin (CLDN) superfamily of tight junction proteins has been reported in breast cancer. The aim of this study was to examine the immunohistochemical expression of CLDN 12 and its prognostic significance in breast cancer tissues. METHODS: Immunohistochemical expression of CLDN 12 was performed on tissue microarrays consisting of 232 cases of breast carcinoma and correlated with clinicopathological features as well as survival of the patients with breast cancer. RESULTS: For the estrogen receptor (ER)-negative subgroup of patients with breast cancer, CLDN 12 expression was shown to be an independent predictor of poor overall survival (HR=2.345; p=0.020) and disease-free survival (HR=2.177; p=0.026) but not for the ER-positive tumours. CONCLUSIONS: The findings suggest that CLDN 12 expression could be clinically useful for predicting the survival of the ER-negative subgroup of patients with breast cancer. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
AIMS: Altered expression of the Claudin (CLDN) superfamily of tight junction proteins has been reported in breast cancer. The aim of this study was to examine the immunohistochemical expression of CLDN 12 and its prognostic significance in breast cancer tissues. METHODS: Immunohistochemical expression of CLDN 12 was performed on tissue microarrays consisting of 232 cases of breast carcinoma and correlated with clinicopathological features as well as survival of the patients with breast cancer. RESULTS: For the estrogen receptor (ER)-negative subgroup of patients with breast cancer, CLDN 12 expression was shown to be an independent predictor of poor overall survival (HR=2.345; p=0.020) and disease-free survival (HR=2.177; p=0.026) but not for the ER-positive tumours. CONCLUSIONS: The findings suggest that CLDN 12 expression could be clinically useful for predicting the survival of the ER-negative subgroup of patients with breast cancer. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Entities:
Keywords:
BREAST CANCER; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY
Authors: Heidi K Baumgartner; Michael C Rudolph; Palaniappian Ramanathan; Valerie Burns; Patricia Webb; Benjamin G Bitler; Torsten Stein; Ken Kobayashi; Margaret C Neville Journal: J Mammary Gland Biol Neoplasia Date: 2017-04-28 Impact factor: 2.673